Tema Etfs LLC bought a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 20,215 shares of the biotechnology company's stock, valued at approximately $813,000.
A number of other large investors have also recently bought and sold shares of VKTX. S.A. Mason LLC grew its holdings in shares of Viking Therapeutics by 20.0% in the 4th quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company's stock worth $72,000 after purchasing an additional 300 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Viking Therapeutics by 75.9% during the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock worth $29,000 after buying an additional 309 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich raised its stake in shares of Viking Therapeutics by 7.4% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,980 shares of the biotechnology company's stock valued at $221,000 after acquiring an additional 345 shares during the last quarter. Arizona State Retirement System grew its position in Viking Therapeutics by 1.2% during the 4th quarter. Arizona State Retirement System now owns 28,929 shares of the biotechnology company's stock worth $1,164,000 after acquiring an additional 353 shares during the last quarter. Finally, Activest Wealth Management grew its position in Viking Therapeutics by 24.1% during the 4th quarter. Activest Wealth Management now owns 2,165 shares of the biotechnology company's stock worth $87,000 after acquiring an additional 420 shares during the last quarter. 76.03% of the stock is currently owned by institutional investors.
Viking Therapeutics Price Performance
Shares of Viking Therapeutics stock traded down $0.69 during trading hours on Friday, hitting $27.04. The company's stock had a trading volume of 746,374 shares, compared to its average volume of 4,065,180. Viking Therapeutics, Inc. has a 12 month low of $18.92 and a 12 month high of $81.73. The company has a market capitalization of $3.04 billion, a PE ratio of -27.02 and a beta of 0.75. The stock has a 50 day moving average of $25.97 and a 200 day moving average of $35.44.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The firm's quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.26) EPS. Equities analysts expect that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.
Wall Street Analyst Weigh In
Several analysts have recently commented on the company. Raymond James increased their target price on Viking Therapeutics from $122.00 to $125.00 and gave the stock a "strong-buy" rating in a report on Thursday, February 6th. Truist Financial restated a "buy" rating and issued a $75.00 price objective (down previously from $95.00) on shares of Viking Therapeutics in a research report on Monday, April 28th. Cantor Fitzgerald upgraded shares of Viking Therapeutics to a "strong-buy" rating in a research report on Tuesday, April 29th. Morgan Stanley lowered their price target on shares of Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Finally, B. Riley reaffirmed a "buy" rating and set a $96.00 price objective (down previously from $109.00) on shares of Viking Therapeutics in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Viking Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $87.15.
View Our Latest Analysis on VKTX
Insider Activity
In other Viking Therapeutics news, Director Sarah Kathryn Rouan acquired 1,240 shares of the business's stock in a transaction dated Monday, March 31st. The shares were acquired at an average price of $24.15 per share, with a total value of $29,946.00. Following the completion of the transaction, the director now directly owns 1,240 shares in the company, valued at $29,946. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.10% of the company's stock.
About Viking Therapeutics
(
Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Stories
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
